Friday, 8 November 2013

Cardiac Fibrosis - Pipeline Review, H2 2013

Reportstack has announced a new market report on Cardiac Fibrosis - Pipeline Review, H2 2013 which provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Cardiac Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cardiac Fibrosis. Cardiac Fibrosis - Pipeline Review, Half Year is built using data and information sourced from databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team of members.

Scope

- A snapshot of the global therapeutic scenario for Cardiac Fibrosis.
- A review of the Cardiac Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Cardiac Fibrosis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Cardiac Fibrosis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Cardiac Fibrosis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

The Companies Mentioned  in this report are Merck & Co., Inc. BioLineRx, Ltd. Digna Biotech, S.L. miRagen Therapeutics, Inc. Fibrotech Therapeutics Pty. Ltd.

To view the table of contents and know more details please visit Cardiac Fibrosis - Pipeline Review, H2 2013 report.

Athlete's Foot (Tinea Pedis) - Pipeline Review, H2 2013

Reportstack has announced a new market report on Athlete's Foot (Tinea Pedis) - Pipeline Review, H2 2013 which provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Athlete's Foot (Tinea Pedis), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Athlete's Foot (Tinea Pedis). Athlete's Foot (Tinea Pedis) - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team of members.

Scope

- A snapshot of the global therapeutic scenario for Athlete's Foot (Tinea Pedis).
- A review of the Athlete's Foot (Tinea Pedis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Athlete's Foot (Tinea Pedis) pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Athlete's Foot (Tinea Pedis).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Athlete's Foot (Tinea Pedis) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

The Companies Mentioned in this report are Valeant Pharmaceuticals International Watson Pharmaceuticals, Inc. Quinnova Pharmaceuticals, Inc. Helix BioMedix, Inc. Anacor Pharmaceuticals, Inc. Viamet Pharmaceuticals, Inc. FTA Therapeutics, LLC Laboratorio Teuto Brasileiro.

To view the table of contents and know more details please visit Athlete's Foot (Tinea Pedis) - Pipeline Review, H2 2013 report.

Arrhythmias - Pipeline Review, H2 2013

Reportstack has announced a new market report on Arrhythmias - Pipeline Review, H2 2013 which provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Arrhythmias, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Arrhythmias. Arrhythmias - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team of members.

Scope

- A snapshot of the global therapeutic scenario for Arrhythmias.
- A review of the Arrhythmias products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Arrhythmias pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Arrhythmias.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Arrhythmias pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

The Companies Mentioned in this report are Gilead Sciences, Inc. Forest Laboratories, Inc. Pfizer Inc.

To view the table of contents and know more details please visit Arrhythmias - Pipeline Review, H2 2013 report.

Anesthetic Effect - Pipeline Review, H2 2013

Reportstack has announced a new market report on Anesthetic Effect - Pipeline Review, H2 2013 which provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Anesthetic Effect, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anesthetic Effect. Anesthetic Effect - Pipeline Review, Half Year is built using data and information sourced from databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team of members.

Scope

- A snapshot of the global therapeutic scenario for Anesthetic Effect.
- A review of the Anesthetic Effect products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Anesthetic Effect pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Anesthetic Effect.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Anesthetic Effect pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.


The Companies Mentioned in this report are Merck & Co., Inc. Physica Pharma Lipicard Technologies Limited Novaliq GmbH Maruishi Pharmaceutical Co., Ltd.

To view the table of contents and know more details please visit  Anesthetic Effect - Pipeline Review, H2 2013 report

Vitiligo - Pipeline Review, H2 2013

Reportstack has announced a new market report on Vitiligo - Pipeline Review, H2 2013 which provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Vitiligo, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Vitiligo. Vitiligo - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team of members.

Scope

- A snapshot of the global therapeutic scenario for Vitiligo.
- A review of the Vitiligo products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Vitiligo pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Vitiligo.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Vitiligo pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

The Companies Mentioned in this report are Reliance Life Sciences Pvt. Ltd. Galderma S.A. Sun Pharmaceutical Industries Limited Clinuvel Pharmaceuticals Limited Ache Laboratorios Farmaceuticos S/A SWITCH Biotech LLC

To view the table of contents and know more details please visit Vitiligo - Pipeline Review, H2 2013 report.

Thursday, 7 November 2013

Alzheimer's Disease Therapeutics Market to 2019

Reportstack has announced a new market report on Alzheimer's Disease Therapeutics Market to 2019.  “Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth” Currently there are a number of disease-modifying drugs in the Multiple Sclerosis (MS) market that are indicated for the treatment of relapsing forms of the disease, specifically reducing the frequency of disease relapses. The market is led by Copaxone, which achieved global sales of $4 billion in 2012. Over the forecast period 2012–2019, a variety of new drugs are due to enter the market that will offer a vast improvement in efficacy but also convenience, as many of these drugs are orally administered. Additionally, a high number of monoclonal Antibodies (mAbs) are due to enter the market and diversify it in terms of its portfolio for late stage or aggressive MS. All of these drugs have been shown to offer substantial improvements over current therapies. The price of these new therapies is expected to be high, particularly for the mAbs, but this is unlikely to hinder their uptake. As a result of this, as well as an overall increase in the treated population, GBI Research believes the global market has the potential to grow to a value of $17.9 billion by 2019.

Scope
-  A brief introduction to MS, including the disease’s history, pathogenesis, risk factors and diagnosis.
-  In-depth analysis of the eight major disease-modifying drugs for MS, including analyses of their safety, efficacy, treatment patterns and strengths/weaknesses. Includes a heat map comparing the drugs in terms of safety and efficacy.
-  Comprehensive review of the pipeline for MS therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets, as well as administration routes.
-  Additional analysis of pipeline drug clinical trials by phase, molecule type, trial size and trial duration.
-  Multi-scenario forecast model of the market, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology.
-  Discussion of the drivers and barriers for market growth or decay.

Reasons to Buy
-  Understand the different levels of MS therapies, from early-stage/mild MS to late-stage/aggressive MS.
-  Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent.
-  Observe the trends in clinical trial duration and size amongst clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for multiple sclerosis therapeutics.
-  Observe the shift in clinical trial endpoints with clinical phase, and use this data to potentially influence any future developmental programs.
-  Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the multiple sclerosis therapeutics market.

Related Industry Reports

Alzheimer’s Disease Therapeutics Market to 2019 - Early Stage Innovation Points to Disease Modifying Therapies and Market Transformation
ADHD Therapeutics Market to 2018 - New Diagnostic Parameters for Adult ADHD Offer Hope for Higher Rates of Treatment
Neurodegenerative Diseases Market to 2018 - New Product Entries in Both Niche and Broader Parkinson’s Disease Treatment will Boost Market Despite Patent Cliff
Orphan Diseases Therapeutics in CNS to 2017-Novel Agents such as AMR101 and ACR16 to Provide Treatment Options and Boost the Huntington’s Disease Segment
Antipsychotics Market to 2017 - Patent Expiries for Zyprexa, 

To view the table of contents and know more details please visit  Alzheimer's Disease Therapeutics Market to 2019 report.

Global and China Plastic Injection Molding Machine Industry Report, 2013

Reportstack has announced a new market research publication on Global and China Plastic Injection Molding Machine Industry Report, 2013. The annual output of injection molding machines in China, the world’s largest injection molding machine producer, hit roughly 100,000 sets. However, impacted by the weakening demand for auto and household appliances downstream on the heels of slowdown in the growth of Chinese economy, China’s output of injection molding machines slowed down in growth since 2011H2, and even witnessed negative growth in 2012. Nevertheless, China injection molding machine market showed stable momentum from 2013Q2, with the expected annual output growing by around 2.5% over the preceding year.

Meanwhile, China also boasts a major trader of injection molding machines in the world. 2012 witnessed a notable turning point in terms of trading in China injection molding machine industry, with the export exceeding the import for the first time, and with the trade surplus amounting to USD111.85 million. In 2013, the trade surplus further expanded, with the value in the first eight months hitting USD150.30 million. This came as the following two aspects: firstly, more and more overseas manufacturers are establishing injection molding machine works in China, fueling the export of injection molding machines; secondly, China’s sluggish demand in recent two years caused the decline in import. Rather, some of western economies are emerging from its doldrums, creating better conditions for investment and generating import of injection molding machines. The report emphasizes the production , sales, and import & export of global and China injection molding machine industry, dwells on the market breakdown of all-electric, all-hydraulic and two-plate models, and highlights six international tycoons including Arburg, Sumitomo (SHI) Demag, Engel and NISSEI Plastic Industrial as well as 14 domestic enterprises including Haitian International Holdings Limited, The Chen Hsong Group, L.K. Technology Holdings Limited, Cosmos Machinery Enterprises Limited, FU CHUN SHIN Machinery Manufacture, Borch Machinery and Guangdong Yizumi Precision Machinery.

Arburg boasts the world’s leading injection molding machine producer which has established branches in Hong Kong, Shanghai and Shenzhen. In particular, the Shanghai outlet is its focus in China, providing mid to high-end products such as metal powder injection molding machines, liquid silicone injection molding machines, and thermal plastic injection molding machines in a modular approach. In Jul. 2013, Arburg set up injection molding machine spot warehouse in Shanghai, in an aim to offer better service for clients across Asia.

Sumitomo (SHI) Demag has four injection molding machine production bases located at Schwaig and Wiehe of Germany, Japan and Ningbo of China. In Aug.2013, Demag input EUR7 million in China earmarked for expanding the capacities of injection molding machines in the Ningbo base, with the targeted capacities increasing from 650 sets to 1,000-3,000 sets.

Haitian International Holdings Limited, the world’s largest injection molding machine manufacturer, has set up distribution networks in China, Germany, Brazil, Turkey, and Vietnam. In 2012, its output of injection molding machines hit 22,000 sets, with the sales amounting to RMB6.336 billion. In 2013, it planned to build the 12th and 13th branches in Ningbo specializing in the production of all-electric and large-sized injection molding machines, respectively.

FU CHUN SHIN Machinery Manufacture, the largest injection molding machine manufacturer in Taiwan, owns three production bases in Ningbo, Dongguan and Taiwan, with the annual capacity hitting 3,160 sets. In 2012, the revenue of the company claimed NTD1.654 billion, of which, NTD1.012 billion from injection molding machine business. In Oct.2013, the company set a target to realize the revenue of NTD6 billion by 2018. In addition, it is poised to strength its commercial arm towards overseas market through building one to two injection molding machine production bases in Brazil and Indonesia in coming five years as well as three to five self-support footholds in the Philippines and India.

To view the table of contents and know more details please visit  Global and China Plastic Injection Molding Machine Industry Report, 2013